Login
$TVGN
$6.22 +$0.22 (3.67%) Live

$TVGN SEC Filings

Filed On Filing
16 Nov 2026 10-Q
04 Nov 2026 SCHEDULE 13D/A
04 Nov 2026 Form 4: Saadi Ryan H., Director

Received 50,000,000 shares as a grant or award

04 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

On November 2, 2026, Susan Podlogar gave notice of her resignation from service as a director of Tevogen Inc. (the “Company”), effective immediately. In connection with Ms. Podlogar’s resignation, the Company’s Board of Directors (the “B...

03 Nov 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

THIS FIRST AMENDMENT TO LOAN AGREEMENT (this “Amendment”), dated as of October 27, 2026, between TEVOGEN INC. (formerly known as Tevogen Bio Holdings Inc.), a Delaware corporation, as borrower (“Borrower”) and The Patel Family, LLP, a De...

30 Sep 2026 8-K: Other Events

Both previously disclosed Nasdaq compliance matters are now closed

16 Sep 2026 SCHEDULE 13D/A
16 Sep 2026 SCHEDULE 13D/A
16 Sep 2026 Form 4: Saadi Ryan H., Director

Received 8,000,000 shares as a grant or award

16 Sep 2026 Form 4: Desai Kirti, Chief Financial Officer

Received 750,000 shares as a grant or award

16 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

Tevogen Inc., a Delaware corporation (the “Company”), hereby grants shares of the Company’s common stock, par value $0.0001 per share (the “Stock”), to the Grantee named below, subject to the vesting conditions set forth below (such gran...

15 Sep 2026 Form 4: Goh Keow Lin, Director

Received 75,000 shares as a grant or award

15 Sep 2026 Form 4: Podlogar Susan M, Director

Received 75,000 shares as a grant or award

15 Sep 2026 Form 4: Sordillo Victor J., Director

Received 75,000 shares as a grant or award

15 Sep 2026 Form 4: Feike Jeffrey L., Director

Received 75,000 shares as a grant or award

15 Sep 2026 Form 4: Patton Curtis L., Director

Received 75,000 shares as a grant or award

10 Sep 2026 8-K: Other Events

On September 9, 2026, Tevogen Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had regained compliance with the $15 million minimum market value of publicly held share...

26 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

THIS AMENDMENT NO. 2 (this “Amendment”) to the Tevogen Inc. 2024 Omnibus Incentive Plan (the “Plan”), which increases the number of shares available for issuance under the Plan by 100,000,000 shares, was adopted by the Board of Directors...

24 Aug 2026 S-8
14 Aug 2026 10-Q

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support